A Single Center, Open-label, Randomized, Controlled Pilot Trial to Evaluate the Efficacy and Safety of Everolimus Conversion Versus Standard Immunosuppression in Liver Transplant Recipients

Trial Profile

A Single Center, Open-label, Randomized, Controlled Pilot Trial to Evaluate the Efficacy and Safety of Everolimus Conversion Versus Standard Immunosuppression in Liver Transplant Recipients

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Aug 2017

At a glance

  • Drugs Everolimus (Primary) ; Corticosteroids; Mycophenolic acid; Tacrolimus
  • Indications Liver transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Aug 2017 Planned End Date changed from 1 Oct 2017 to 1 Feb 2019.
    • 09 Aug 2017 Planned primary completion date changed from 1 Oct 2016 to 1 Jun 2018.
    • 09 Dec 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top